Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL

Inclusion Criteria:

• subjects with a primary diagnosis of B-ALL who have any of the following: (a) nosuitable allogeneic HSCT donor. (b) refusal of allogeneic HSCT.

• positive expression of CD19 in peripheral blood or bone marrow primary cellsdetected by flow cytometry.

• ardiac ultrasound left ventricular ejection fraction ≥ 50%; Creatinine ≤ 1.6 mg/dl;alanine transaminase (ALT) and aspartate aminotransferase (AST) ≤ 3 times the normalrange and total bilirubin ≤ 2.0 mg/dl; Pulmonary function ≤ grade 1 dyspnea (CTCAEv5.0) with oxygen saturation > 91% without oxygenation.

• subjects aged 15-65 years (including 15 and 65 years), regardless of gender.

• T-cell amplification test pass.

• expected survival > 3 months.

Exclusion Criteria:

• patients with recurrence of only isolated extramedullary lesions. combination ofother malignant tumors.

• previously treated with anti-CD19 therapies.

• immunosuppressants use within 2 weeks prior to signing informed consent or plan toimmunosuppressants after signing informed consent.

• uncontrolled active infections.

• HIV infection.

• active hepatitis B or hepatitis C infection.

• history of severe tachyphylaxis to aminoglycoside antibiotics.

• history or presence of clinically relevant Central Nervous System (CNS) pathology,such as epilepsy, generalized seizure disorder, paresis, aphasia, stroke, severebrain injuries, dementia, Parkinson's disease, cerebellar disease, organic brainsyndrome, or psychosis.